Evidence map›Paper›PMID 40094098›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2025

Xenogeneic-free platform for the isolation and scalable expansion of human bladder smooth muscle cells.

Teresa Franchi-Mendes, Marília Silva, Maria Catarina Carreira, Ana Luísa Cartaxo, Paulo Vale, Panagiotis Karakaidos, Apostolos Klinakis, Ana Fernandes-Platzgummer, Cláudia L da Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Teresa Franchi-MendesDepartment of Bioengineering and iBB - Institute for Bioengineering and Biosciences at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
Marília SilvaDepartment of Bioengineering and iBB - Institute for Bioengineering and Biosciences at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
Maria Catarina CarreiraDepartment of Bioengineering and iBB - Institute for Bioengineering and Biosciences at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
Ana Luísa CartaxoDepartment of Bioengineering and iBB - Institute for Bioengineering and Biosciences at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
Paulo ValeUrology Department, Hospital CUF Descobertas, Lisboa, Portugal.
Panagiotis KarakaidosBiomedical Research Foundation of the Academy of Athens, Athens, Greece.
Apostolos KlinakisBiomedical Research Foundation of the Academy of Athens, Athens, Greece.
Ana Fernandes-PlatzgummerDepartment of Bioengineering and iBB - Institute for Bioengineering and Biosciences at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
Cláudia L da SilvaDepartment of Bioengineering and iBB - Institute for Bioengineering and Biosciences at Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Smooth muscle cells (SMC) play a crucial role in bladder tissue engineering strategies. Scalable, Good Manufacturing Practice (GMP)-compliant platforms are essential for producing clinically relevant cell numbers. Materials & Methods: A gamma-irradiated human platelet lysate (HPL) supplement was used to develop a xeno(geneic)-free process for the isolation and scalable expansion of human bladder-derived SMC. Results: Cells were isolated using an explant-based technique and expanded ex vivo, expressing typical SMC markers (α-SMA, desmin, caldesmon and SM22-α). Cell culture was successfully scaled-up using spinner flasks combined with plastic microcarriers, starting with a 2.8 × 10 Conclusions: This xeno-free, GMP compliant process enables scalable manufacturing of human bladder-derived SMC while preserving cell identity, potentially advancing clinical applications in bladder engineering.

Indexed as

Bladder tissue engineeringMicrocarrier-based expansionSmooth muscle cellsXeno(geneic)-free

Identifiers

PMID40094098
PMCPMC11909460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.